Critical reviews in oncology/hematology
-
Crit. Rev. Oncol. Hematol. · Jul 2020
ReviewAdvances in adjuvant therapy of biliary tract cancer: an overview of current clinical evidence based on phase II and III trials.
Patients with biliary tract cancer (BTC) have a high recurrence rate after complete surgical resection. To reduce the risk of recurrence and to improve survival, several chemotherapeutic agents that have shown to be active in locally advanced and metastatic BTC have been investigated in the adjuvant setting in prospective clinical trials. ⋯ Ongoing randomized controlled trials mainly compare capecitabine with gemcitabine-based chemotherapy or chemoradiotherapy. This review provides an update of adjuvant therapy in BTC based on published data of phase II and III trials and ongoing randomized controlled trials (RCTs).